Long-term course of Crohn s disease in Japan: Incidence of complications, cumulative rate of initial
|
|
- Poppy Reeves
- 5 years ago
- Views:
Transcription
1 Original Article: Alimentary Tract Long-term course of Crohn s disease in Japan: Incidence of complications, cumulative rate of initial surgery, and risk factors at diagnosis for initial surgery Yuho Sato 1), Toshiyuki Matsui 1), Yutaka Yano 1), Kozue Tsurumi 1), Yuki Okado 1), Yu Matsushima 1), Akihiro Koga 1), Haruhiko Takahashi 1), Kazeo Ninomiya 1), Yoichiro Ono 1), Noritaka Takatsu 1), Takahiro Beppu 1), Takashi Nagahama 1), Takashi Hisabe 1), Yasuhiro Takaki 1), Fumihito Hirai 1), Kenshi Yao 1), Daijiro Higashi 2), Kitaro Futami 2), Masakazu Washio 3) 1) Department of Gastroenterology, Fukuoka University Chikushi Hospital, Fukuoka, Japan 2) Department of Surgery, Fukuoka University Chikushi Hospital, Fukuoka, Japan 3) Department of Community Health and Clinical Epidemiology, St. Mary s College, Kurume, Japan Corresponding author: Toshiyuki Matsui 1
2 Department of Gastroenterology, Fukuoka University Chikushi Hospital Zokumyoin, Chikushino, Fukuoka , Japan Tel: ; Fax: Short title: Long-term course of Crohn s disease in Japan 2
3 Abstract Background and Aims: Intestinal complications of stenosis or fistula may occur during the course of Crohn s disease (CD), and surgery is performed in a fair number of patients. The risk factors for initial surgery in a Japanese hospital-based cohort of CD patients were evaluated. Methods: This study was a single-center, retrospective, cohort study. The subjects were 520 patients who underwent inpatient and outpatient treatment at our hospital, had a definitive diagnosis of CD, and no previous surgery. Three parameters were investigated: 1) cumulative incidence of stenosis and fistula; 2) cumulative rate of initial surgery for each disease type; and 3) risk factors at diagnosis for initial surgery. Results: 1) Stenosis and fistula increased with time, with stenosis or fistula appearing in about half of the patients after 5 years. 2) The cumulative rate of initial surgery was about 50% after 10 years. 3) The patient factors at diagnosis of current smoker, upper gastrointestinal disease, stricturing, penetrating, moderate to severe stenosis of the jejunum, moderate to severe stenosis of the ileum, and moderate to severe stenosis of the terminal ileum were risk factors for initial surgery. 3
4 Conclusions: Stenosis or fistula appeared in about half of the patients after 5 years from diagnosis. When upper gastrointestinal disease or complicated small intestinal lesions are seen at the time of diagnosis, the cumulative rate of initial surgery is significantly higher. Keywords Crohn s disease, stenosis, fistula, cumulative rate of initial surgery, risk factor for initial surgery 4
5 Introduction Crohn s disease (CD) is a chronic inflammatory disease of the gastrointestinal tract characterized by granulomatous inflammation of all layers and a discontinuous distribution. It is also known to affect all parts of the gastrointestinal tract from the mouth to the anus. The occurrence of stenosis or fistula as intestinal complications is not uncommon. These complications are especially common in long-term cases, and it is not unusual for patients to undergo frequent surgery. Since the report of Crohn et al. in 1932 [1], there have been many reports in Western countries of the long-term course associated with these intestinal complications and the rate of surgery [2-6]; whereas in Japan, this research topic has only been investigated relatively recently, and few reports have described and statistically analyzed the long-term prognosis based on course observation in a large number of patients. In this study, a database was created from long-term observations of 520 patients, and the cumulative rate of initial surgery and patient factors affecting that rate were studied to investigate the prognosis. The cumulative incidences of stenosis and fistula, the typical intestinal complications that are the main reasons for these 5
6 surgeries, were also investigated during the long-term course. 6
7 Methods Study design and patient population This study was a single-center, retrospective, cohort study. A database of all CD patients treated at the Department of Gastroenterology, Fukuoka University Chikushi Hospital was created and used in this study. All inpatient and outpatient records from 1985 to 2010 were reviewed, and the database was created by retrospectively inputting each patients parameters (approximately 100), based on level of severity. The parameters included sex, age, date of diagnosis, date of initial surgery, symptoms, Crohn s disease activity index, extra-intestinal complications, malignant tumors, imaging findings including endoscopy and X-ray examinations, severity of stenosis, fistula details, abscess, and social activity. Creation of this database took three years, from 2008 to As of May 2010, 719 patients had been registered; 167 patients who had already undergone surgery at another hospital prior to their first visit to our hospital were excluded. Moreover, since disease classifications differ in Japan, and there is no disease category of aphthae only in the Montreal classification [7], 29 patients corresponding to this category [8] were also excluded. In addition, 3 patients who 7
8 were observed for less than 3 months were excluded. The remaining 520 patients were the subjects of this study (Fig. 1). All of these patients fulfilled the revised diagnostic criteria for Crohn s disease of the Ministry of Health, Labour and Welfare [9-11] during the course of their disease, and they were definitively diagnosed. Cases that were definitively diagnosed as another disease, such as ulcerative colitis, and cases of uncertain diagnosis that did not meet the diagnostic criteria were excluded from this study. Definitions and endpoints 1) The disease behavior at the time of diagnosis was classified according to the Montreal classification [7] as inflammatory (B1), stricturing (B2), or penetrating (B3), and the cumulative incidence was calculated for each disease behavior, with the date on which the stenosis and fistula occurred or the date of final observation as the endpoint, as in the report by Cosnes et al. [12]. 2) The disease type at the time of diagnosis was classified according to the Montreal classification [7] as ileal type (L1), colonic type (L2), or ileocolonic type (L3), and the cumulative rate of initial surgery was 8
9 calculated for each disease type, with the date of initial surgery or the date of final observation as the endpoint. Surgery was defined as bowel resection or surgery for intestinal complications and did not include small operations for anal lesions or intraperitoneal drainage. Stenosis, fistula, and bleeding were the reasons for surgery. In addition, fistula included both external and internal fistulas. 3) Patient factors at diagnosis were divided into clinical characteristics, age, disease type, disease behavior, morphological changes, and initial treatment. Using these patient factors at diagnosis, the rate of initial surgery was analyzed. The following items were selected as patient factors at diagnosis. Clinical characteristics included male sex and life history, including smoking and drinking; and diagnosis involved, whether or not it was made at our hospital, which specializes in CD. Smokers were defined as current smokers. Alcohol drinkers were defined as those who drank alcohol almost every day. Age, disease type, and disease behavior were classified according to the Montreal classification [7]. Upper gastrointestinal disease (L4) with CD was defined using the Japanese criteria [7-9]: 1. longitudinal ulcer or cobblestone appearance; 2. irregular to 9
10 oval-shaped ulcers or aphthae over a wide area; 3. erosions and aphthae with a trend to a longitudinal array; and 4. bamboo joint-like appearance and notch-like depressions. The lesions fulfilled at least one of the criteria listed above (1-4) in the esophagus, stomach, or duodenum. However, the above applied only to patients in whom other diseases could be excluded. Morphological changes included segments in which moderate to severe stenosis had occurred, with the small intestine divided into jejunum, ileum, and terminal ileum; and segments in which moderate to severe stenosis had occurred, with the colon divided into the three segments of the left colon, right colon, and rectum. Moderate to severe stenosis was determined by double-contrast imaging with a sufficient amount of injected air, and stenosis was defined as stenosis in which the lumen was less than one-half that of neighboring healthy intestine. The initial treatment was the treatment that was provided at the time of diagnosis, and included cases of treatment with more than one agent. Statistical analysis The data were analyzed using Stat View (Stat View for Windows, version 5.0, SAS Institute Inc.). The 10
11 Kaplan-Meier method was used to compare the cumulative incidences of stenosis and fistula and the cumulative rate of initial surgery in each time period, and patient factors affecting initial surgery were analyzed using the Cox proportional hazards model. The log-rank test (Mantel-Cox) was used in tests of significance, with a probability level of 5% indicating a significant difference in all cases. 11
12 Results Table 1 shows the clinical features of the 520 patients with CD. The sex ratio (male: female) was 2.4:1, the mean age at diagnosis was 25.2 ± 10.0 years, and the mean duration of disease was 10.3 ± 7.8 years. The mean observation period (time from diagnosis until first surgery or until final observation date) was 6.6 ± 6.0 years. Overall, 200 patients were current smokers, 165 were alcohol drinkers. Seventy-seven patients had an anal fistula; and L1, L2, L3, and L4 were seen in 199, 84, 237, and 227 patients, respectively. The disease behavior was B1 in 422 patients, B2 in 72 patients, and B3 in 26 patients. Including some cases of multiple treatment, the treatment at the time of diagnosis was 5-aminosalicylate in 251 patients, elemental diet (> 900 kcal/day) in 395 patients, oral corticosteroid in 84 patients, 6-mercaptopurine or azathioprine in 30 patients, and biological agents in 12 patients. 1) Cumulative incidence of stenosis and fistula The cumulative incidence for each disease behavior is shown in Fig. 2. The incidence for each disease behavior at baseline from the day of diagnosis was 81% for B1, 14% for B2, and 5% for B3. The cases were 12
13 mostly B1 at baseline, but after 5 years, the percentages changed to 46%, 35%, and 19%, respectively, for B1, B2, and B3; with B2 and B3 increasing thereafter. 2) Cumulative rate of initial surgery for each disease type There were 277 surgery patients, in whom stenosis, fistula, and bleeding were the main reasons for initial surgery (Table 2). Figure 3 shows the cumulative rate of initial surgery at 5, 10, 15, and 20 years from the time of diagnosis for all 520 patients and patients of each of the three disease types. In all 520 patients, the rate was 32% after 5 years, 55% after 10 years, 70% after 15 years, and 82% after 20 years. By disease type, the rate for L1 was 37% after 5 years, 60% after 10 years, 73% after 15 years, and 85% after 20 years. For L2, it was 19%, 37%, 43%, and 48%, respectively, and for L3, it was 31%, 55%, 73%, and 86%, respectively. In a comparison of L1 and L2, the rate was significantly (p < 0.01) lower with L2. Even between L3 and L2, the rate was significantly (p < 0.05) lower with L2. In contrast, there was no significant difference between L1 and L3. 3) Risk factors at diagnosis for initial surgery Table 3 summarizes the relative risk of initial surgery according to patient factors at diagnosis on univariate 13
14 analysis. Among the patients clinical characteristics, male patients showed an increased age-adjusted risk of initial surgery than female patients, but male sex failed to be a significant risk factor for initial surgery after additional adjustment for smoking and drinking. On the other hand, current smokers showed a significantly higher risk than former smokers and non-smokers even after adjusting for age, sex, and drinking. For age at the diagnosis of CD, there was no meaningful association between age and the risk of initial surgery. Among patient factors of disease type, patients with L2 showed a significantly lower age, sex, smoking, and drinking-adjusted risk of initial surgery than patients with L1, while compared with their counterparts, those with L4 showed a significantly higher risk of initial surgery even after controlling for age, sex, smoking, and drinking. Among patient factors of disease behavior, patients with B2, as well as those with B3, showed a significantly increased age, sex, smoking, and drinking-adjusted risk of initial surgery than those with B1. Among patient factors of morphological changes (i.e., moderate to severe stenosis), those with jejunal stenosis showed a significantly higher risk of initial surgery than those without, even after adjusting for age, sex, smoking, and drinking. Similar findings were observed among those with ileal stenosis and those with terminal 14
15 ileal stenosis. Among patient factors of initial treatment, biological agents showed a hazard ratio higher than one, while oral corticosteroid and 6-mercaptopurine or azathioprine showed a hazard ratio lower than one, but none of them were significant. The relationship with L4 is shown in Table 4, and that with other factors for which there was a significant difference is shown in Table 3. The results show that patients with L4 at the time of diagnosis had a significantly higher percentage of B2 and moderate to severe stenosis of the jejunum at diagnosis. 15
16 Discussion The long-term course of intestinal complications and the surgery rate for CD has been presented in many reports [1-6] in Western countries. However, few reports have described the long-term course in a large number of patients in Asia or in Japan [13, 14]. Therefore, this was investigated in this study. The present results suggested that intestinal complications of stenosis and fistula were the main reasons for intestinal surgery in CD. Stenosis and fistula increased with time, with stenosis or fistula appearing in about half of the patients after 5 years. As may be conjectured from the increase in intestinal complications with time, the cumulative rate of initial surgery also increased with time. The majority of patients had undergone surgery at 10 years after diagnosis. This result is similar to reports from Western countries [2, 6, 15, 16], and the prognosis of CD in Japan was no better than elsewhere. In addition, there was no considerable difference in the cumulative rate of initial surgery even over the course from onset [13, 14]. The cumulative rate of initial surgery was also investigated for each disease type. As shown in Fig. 3, the 16
17 cumulative rate of initial surgery was significantly lower for L2 than for the other disease types. This may also be due to a tendency for surgery to be more likely in cases with small bowel lesions, which was also pointed out in a report by Sands et al. [12, 17] showing that ileal type at the time of diagnosis is a risk factor for surgery. One may understand that the lumen of the small bowel is smaller than that of the large bowel, and the formation of a fistula from stenosis or intestinal obstruction from the stenosis itself is more likely to occur. Regarding the risk for L2, there are several reports of a lower cumulative rate of surgery with L2 than with other disease types in Western countries [15, 18-20]. How patient factors at diagnosis affect this initial surgery was also investigated in this study. The analysis was done for 25 items of clinical characteristics, age, disease type, disease behavior, morphological changes, and initial treatment. Seven factors at diagnosis (current smoker, L4, B2, B3, moderate to severe stenosis of the jejunum, moderate to severe stenosis of the ileum, moderate to severe stenosis of the terminal ileum) were identified as independently associated with an increased risk of initial surgery. Smoking has also been identified as a significant risk factor, which agrees with previous reports [14, 16, 17]. 17
18 Regarding morphological features, upper gastrointestinal disease involvement was identified, but upper gastrointestinal disease involvement has reported as a risk in few investigations to date. Peyrin-Biroulet et al. [16] recently reported upper gastrointestinal disease as a risk factor in addition to factors such as male sex, smoking, and anal fistula for the cumulative incidence of initial surgery from diagnosis. High frequencies of upper gastrointestinal lesions (52-92%) have been reported both in Japan and other countries [21-25], and a similar frequency of upper gastrointestinal lesions was seen in the present study. Moreover, in the proposed diagnostic criteria for CD in Japan [9-11], characteristic gastric and duodenal lesions are given as a secondary diagnostic finding in addition to main findings, and they have come to occupy a more important position even in the diagnosis of upper gastrointestinal disease. As shown in Table 4, patients with L4 at the time of diagnosis included many who also had B2 and moderate to severe stenosis of the jejunum among patient factors at diagnosis. From this result, it may be presumed that patients with L4 at the time of diagnosis are a high risk group for initial surgery. While Beaugerie et al. [26] and Peyrin-Biroulet et al. [16] reported that anal fistulas were a factor related to 18
19 poor prognosis, in the present study, anal fistula was not a risk factor for initial surgery. The reason for this may be that patients visited our hospital with symptoms such as abdominal pain, fever, or anal discomfort before the occurrence of anal fistula. In other words, it may be presumed that the percentage of cases in which anal fistula could be diagnosed at the time of diagnosis was low because patients presented or were referred to our hospital with milder anal lesions. Therefore, while anal fistula may be a risk factor for surgery over the long term, anal fistula at the time of diagnosis does not seem to be a risk factor for initial surgery. The present study has several limitations. First, this study had a long-term course including various treatments, and therapeutic methods over the long-term period were not considered. In particular, there are a number of reports showing improvement in the rate of surgery with biological agents in recent years. However, biological agents were used as maintenance therapy from the time of initial diagnosis in only 12 patients, and no significant differences were seen. Second, there were no detailed data on smoking and drinking. In conclusion, stenosis or fistula appeared in about half of the patients after 5 years. When upper 19
20 gastrointestinal disease or small intestinal lesions are seen at the time of diagnosis, the cumulative rate of initial surgery is significantly higher. Acknowledgments This work was supported by Health and Labour Sciences Research Grants for Research on Intractable Disease from the Ministry of Health, Labor and Welfare of Japan. Conflict of interest The authors declare that they have no conflict of interest. 20
21 References 1. Crohn BB, Ginzburg D, Oppenheimer GD, Regional ileitis: A pathologic and clinical entity. JAMA 1932, 99: Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, Sandborn WJ. The natural history of adult Crohn s disease in population based cohorts. Am J Gastroenterol 2010; 105: Lakatos PL, Golovics PA, David G, Pandur T, Erdelyi Z, Horvath A, et al. Has there been a change in the natural history of Crohn s disease? Surgical rates and medical management in a population based inception cohort from Western Hungary between Am J Gastroenterol 2012; 107: Picco MF, Zubiaurre I, Adluni M, Cangemi JR, Shelton D. Immunomodulators are associated with a lower risk of first surgery among patient with non-penetrating non-stricturing Crohn s disease. Am J Gastroenterol 2009; 104: Thia KT, Sandborn WJ, Harmsen WS, Zinsmeister AR, Loftus EV Jr. Risk factors associated with progression to intestinal complications of Crohn s disease in a population based cohort. Gastroenterology 21
22 2010; 139: Bernell O, Lapidus A, Hellers G. Risk factors for surgery and postoperative recurrence in Crohn s disease. Ann Surg 2000; 231: Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005; 19 (Suppl. A): Tsurumi K, Matsui T, Hirai F, Takatsu N, Yano Yutaka, Hisabe T, et al. Incidence, clinical characteristics, long-term course, and comparison of progressive and non-progressive cases of aphthous-type Crohn s disease: a single-center cohort study. Digestion 2013; 87: Matsui T, Hirai F, Hisabe T. Proposed diagnostic criteria for Crohn s disease. Annual of Research Group of Intractable Inflammatory Bowel Disease subsidized by the Ministry of Health, Labour, and Welfare of Japan. 2011: (in Japanese). 22
23 10. Ueno F, Matsui T, Matsumoto T, Matsuoka K, Watanabe M, Hibi T. Evidence-based clinical practice guidelines for Crohn s disease, integrated with formal consensus of experts in Japan. J Gastroenterol 2013; 48: Hisabe T, Matsui T, Hirai F, Watanabe M. Evalution of diagnostic criteria for Crohn s disease in Japan. J Gastroenterol 2014; 49: Cosnes J, Cattan S, Blain A, Beaugerie L, Carbonnel F, Parc R, et al. Long-term evolution of disease behavior of Crohn s disease. Inflamm Bowel Dis 2002; 8: Gao X, Yang RP, Chen MH, Xiao YL, He Y, Chen BL, et al. Risk factors for surgery and postoperative recurrence: analysis of a south China cohort with Crohn's disease. Scand J Gastroenterol 2012; 47: Song XM, Gao X, Li MZ, Chen ZH, Chen SC, Hu PJ, et al. Clinical features and risk factors for primary surgery in 205 patients with Crohn's disease: analysis of a South China cohort. Dis Colon Rectum 2011; 54:
24 15. Lind E, Fausa O, Gjone E, Mogensen SB. Crohn s disease. Treatment and outcome. Scand J Gastroenterol 1985; 20: Peyrin-Biroulet L, Harmsen WS, Tremaine WJ, Zinsmeister AR, Sandborn WJ, Loftus EV Jr. Surgery in a population-based cohort of Crohn's disease from Olmsted county, Minnesota ( ). Am J Gastroenterol 2012; 107: Sands BE, Arsenault JE, Rosen MJ, Alsahli M, Bailen L, Banks P, et al. Risk of early surgery for Crohn's disease: implications for early treatment strategies. Am J Gastroenterol 2003; 98: Farmer RG, Whelan G, Fazio VW. Long-term follow-up of patients with Crohn s disease. Gastroenterology 1985; 88: Harper PH, Fazio VW, Lavery IC, Jagelman DG, Weakley FL, Farmer RG, et al. The long term outcome in Crohn s disease. Dis Colon Rectum 1987; 30: Mekhjian HS, Switz DM, Watts HD, Deren JJ, Katon RM, Beman FM. National cooperative Crohn s disease after surgery. Gastroenterology 1979; 77:
25 21. Matsumura M, Matsui T, Hatakeyama A, Matake H, Uno H, Sakurai T, et al. Prevalence of Helicobactor pylori infection and correlation between severity of upper gastrointestinal lesions and H. pylori infection in Japanese patients with Crohn s disease. J Gastroenterol 2001; 36: Cameron DJ. Upper and lower gastrointestinal endoscopy in children and adolescents with Crohn s disease: a prospective study. J Gastroenterol hepatol 1991; 6: Nugent FW, Roy MA. Duodenal Crohn s disease: an analysis of 89 cases. Am J Gastroenterol 1989; 84: Kundhal PS, Stormon MO, Zachos M, Critch JN, Cutz E, Griffiths AM. Gastral antral biopsy in the differentiation of pediatric colitides. Am J Gastroenterol 2003; 98: Castellaneta SP, Afzal NA, Greenberg M, Deere H, Davies S, Murch SH, et al. Diagnostic role of upper gastrointestinal endoscopy in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2004; 39: Beaugerie L, Seksik P, Nion-Larmurier I, Gendre JP, Cosnes J. Predictors of Crohn s disease. 25
26 Gastroenterology 2006; 130:
27 Figure legends Figure 1. Of 719 hospitalized patients as of May 2010, 520 patients remained after exclusion criteria were applied. One hundred sixty-seven patients who had already undergone surgery at another hospital prior to their first visit to our hospital and 29 patients with aphthae only were excluded. Another 3 patients who were observed for less than 3 months were excluded. Figure 2. Cumulative incidences of fistula (upper solid line) and stenosis (lower broken line) from the time of diagnosis in 520 patients. The follow-up number over time is also shown. Figure 3. Cumulative rate of initial surgery for each disease type. Ileal type (L1) and ileocolonic type (L3) have significantly higher rates than colonic type (L2). 27
28 28
29 29
30 30
31 31
32 32
33 33
34 34
Crohn s disease-specific mortality: a 30-year cohort study at a tertiary referral center in Japan
J Gastroenterol (2019) 54:42 52 https://doi.org/10.1007/s00535-018-1482-y ORIGINAL ARTICLE ALIMENTARY TRACT Crohn s disease-specific mortality: a 30-year cohort study at a tertiary referral center in Japan
More informationCrohn s Disease: Should We Treat Based on Symptoms or Based on Objective Markers of Inflammation?
Crohn s Disease: Should We Treat Based on Symptoms or Based on Objective Markers of Inflammation? Edward V. Loftus, Jr., M.D. Professor of Medicine Division of Gastroenterology and Hepatology Mayo Clinic
More informationCrohn disease is a chronic inflammatory bowel disease
GASTROENTEROLOGY 2010;139:1147 1155 Risk Factors Associated With Progression to Intestinal Complications of Crohn s Disease in a Population-Based Cohort KELVIN T. THIA,*, WILLIAM J. SANDBORN,* WILLIAM
More informationEffectiveness of Concomitant Enteral Nutrition Therapy and Infliximab for Maintenance Treatment of Crohn s Disease in Adults
Dig Dis Sci (2013) 58:1329 1334 DOI 10.1007/s10620-012-2374-2 ORIGINAL ARTICLE Effectiveness of Concomitant Enteral Nutrition Therapy and Infliximab for Maintenance Treatment of Crohn s Disease in Adults
More informationTrough level of infliximab is useful for assessing mucosal healing in Crohn s disease: a prospective cohort study
ORIGINAL ARTICLE pissn 1598-91 eissn 2288-1956 https://doi.org/1.5217/ir.218.16.2.223 Intest Res 218;16(2):223-232 Trough level of infliximab is useful for assessing mucosal healing in Crohn s disease:
More informationPredicting the natural history of IBD. Séverine Vermeire, MD, PhD Department of Gastroenterology University Hospital Leuven Belgium
Predicting the natural history of IBD Séverine Vermeire, MD, PhD Department of Gastroenterology University Hospital Leuven Belgium Patient 1 Patient 2 Age 22 Frequent cramps and diarrhea for 6 months Weight
More informationAnus,Rectum and Colon
JOURNAL OF THE Anus,Rectum and Colon http://journal-arc.jp ORIGINAL RESEARCH ARTICLE Risk factors for recurrence of Crohn s disease requiring surgery in patients receiving post-operative anti-tumor necrosis
More informationGuided by Dr. Michal Amitai Head of Abdominal Imaging Department of Diagnostic Imaging Sheba Medical Center Sackler School of Medicine, Tel Aviv
Guided by Dr. Michal Amitai Head of Abdominal Imaging Department of Diagnostic Imaging Sheba Medical Center Sackler School of Medicine, Tel Aviv University 1 SHARE study My year Collaboration between gastroenterology
More informationT he treatment strategy for Crohn s disease (CD) is
237 INFLAMMATORY BOWEL DISEASE Impact of the increasing use of immunosuppressants in Crohn s disease on the need for intestinal surgery J Cosnes, I Nion-Larmurier, L Beaugerie, P Afchain, E Tiret, J-P
More informationBeyond Anti TNFs: positioning of other biologics for Crohn s disease. Christina Ha, MD Cedars Sinai Inflammatory Bowel Disease Center
Beyond Anti TNFs: positioning of other biologics for Crohn s disease Christina Ha, MD Cedars Sinai Inflammatory Bowel Disease Center Objectives: To define high and low risk patient and disease features
More informationCan We Predict the Natural History of Ulcerative Colitis? Edward V Loftus, Jr, MD Professor of Medicine Mayo Clinic Rochester, Minnesota, USA
Can We Predict the Natural History of Ulcerative Colitis? Edward V Loftus, Jr, MD Professor of Medicine Mayo Clinic Rochester, Minnesota, USA Endpoints Overview Hospitalization Surgery Colorectal cancer
More informationCharacteristic Phenotypes in Korean Crohn s Disease Patients Who Underwent Intestinal Surgery for the Treatment
ORIGINAL ARTICLE Gastroenterology & Hepatology http://dx.doi.org/10.3346/jkms.2013.28.4.575 J Korean Med Sci 2013; 28: 575-579 Characteristic Phenotypes in Korean Crohn s Disease Patients Who Underwent
More information11/13/11. Biologics for CD and CUC: The Impact on Surgical Outcomes. Principles of Successful Intestinal Surgery
Biologics for CD and CUC: The Impact on Surgical Outcomes Robert R. Cima, M.D., M.A. Associate Professor of Surgery Division of Colon and Rectal Surgery Overview Antibody based medications (biologics)
More informationResearch Article Endoscopic and Pathologic Changes of the Upper Gastrointestinal Tract in Crohn s Disease
BioMed Research International, Article ID 610767, 6 pages http://dx.doi.org/10.1155/2014/610767 Research Article Endoscopic and Pathologic Changes of the Upper Gastrointestinal Tract in Crohn s Disease
More informationTerumitsu; Nagayasu, Takeshi
NAOSITE: Nagasaki University's Ac Title Author(s) Citation A rare case of segmental ulcerative Tominaga, Tetsuro; Nonaka, Takashi; Shuichi; Kunizaki, Masaki; Sumida, Terumitsu; Nagayasu, Takeshi Acta medica
More informationDifferentiation Between Ileocecal Tuberculosis and Crohn s Disease using a Combination of Clinical, Endoscopic and Histological Characteristics
38 Original Article Differentiation Between Ileocecal Tuberculosis and Crohn s Disease using a Combination of Clinical, Endoscopic and Histological Characteristics Anuchapreeda S Leelakusolvong S Charatcharoenwitthaya
More informationCROHN S DISEASE. The term "inflammatory bowel disease" includes Crohn's disease and the other related condition called ulcerative colitis.
CROHN S DISEASE What does it consist of? Crohn s disease is an inflammatory process that affects mostly to the intestinal tract, although it can affect any other part of the digestive apparatus from the
More informationCitation for the original published paper (version of record):
http://www.diva-portal.org Postprint This is the accepted version of a paper published in Scandinavian Journal of Gastroenterology. This paper has been peer-reviewed but does not include the final publisher
More informationPercent Cumulative. Probability. Penetrating. Inflammatory. Stricturing. Months Patients at risk N =
Fistulizing Crohn s Disease Edward V. Loftus, Jr., M.D. Professor of Medicine Division of Gastroenterology & Hepatology Mayo Clinic Rochester, Minnesota, USA Outline Fistulizing Crohn s Etiology Incidence
More informationCrohn s disease is a chronic recurrent inflammation of the
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2007;5:1430 1438 Clinical Course in Crohn s Disease: Results of a Norwegian Population-Based Ten-Year Follow-Up Study INGER CAMILLA SOLBERG,* MORTEN H. VATN, OLE
More informationDisease behavior in adult patients- are there predictors for stricture or fistula formation?
Disease behavior in adult patients- are there predictors for stricture or fistula formation? Falk Symposium 168, Madrid, Spain Iris Dotan, M.D., Head, IBD Center, Department of Gastroenterology and Liver
More informationTreatment Goals. Current Therapeutic Pyramids Crohn s Disease Ulcerative Colitis 11/14/10
Current Management of IBD: From Conventional Agents to Biologics Stephen B. Hanauer, M.D. University of Chicago Treatment Goals Induce and maintain response/ remission Prevent complications Improve quality
More informationInitiation of Maintenance Treatment in Moderate to Severe New Onset Crohn s Disease
Initiation of Maintenance Treatment in Moderate to Severe New Onset Crohn s Disease The Case for Starting with Anti-TNFα Agents Maria Oliva-Hemker, M.D. Chief, Division of Pediatric Gastroenterology &
More informationFibrotic complications of inflammatory bowel disease
January 27th 2017, 8th Gastro Foundation Weekend for Fellows; Spier Hotel & Conference Centre, Stellenbosch Fibrotic complications of inflammatory bowel disease Gerhard Rogler, Department of Gastroenterology
More informationIBD-Related Lymphoma
IBD-Related Lymphoma Larry Burgart MD Staff Pathologist, Allina Health and Minnesota Gastroenterology Clinical Professor of Pathology, University of Minnesota College of Medicine IBD-Related Lymphoma
More informationINFLAMMATORY BOWEL DISEASE. Jean-Paul Achkar, MD Center for Inflammatory Bowel Disease Cleveland Clinic
INFLAMMATORY BOWEL DISEASE Jean-Paul Achkar, MD Center for Inflammatory Bowel Disease Cleveland Clinic WHAT IS INFLAMMATORY BOWEL DISEASE (IBD)? Chronic inflammation of the intestinal tract Two related
More informationCrohn s disease is a chronic idiopathic disease of the
GASTROENTEROLOGY 1999;117:49 57 Clinical Course and Costs of Care for Crohn s Disease: Markov Model Analysis of a Population-Based Cohort MARC D. SILVERSTEIN,*,, EDWARD V. LOFTUS, Jr., WILLIAM J. SANDBORN,
More informationCrohn's disease CAUSES COURSE OF CROHN'S DISEASE TREATMENT. Sulfasalazine
Crohn's disease Crohn's disease is an inflammatory condition of the digestive tract that affects children and adults. Common features of Crohn's disease include mouth sores, diarrhea, abdominal pain, weight
More informationPD Dr. med. R. Wiest / Dr. med. P. Juillerat, MSc. Donnerstag 18 ten Oktober 2012 UPDATE PROKTOLOGIE: Konservative Behandlungsmöglichkeiten?
PD Dr. med. R. Wiest / Dr. med. P. Juillerat, MSc Donnerstag 18 ten Oktober 2012 UPDATE PROKTOLOGIE: Fisteln bei M. Crohn : Konservative Behandlungsmöglichkeiten? INTERDISZIPLINÄRE VISZERALE CHIRURGIE
More informationEfficacy of Adalimumab in Korean Patients with Crohn s Disease
Gut and Liver, Vol. 10, No. 2, March 2016, pp. 255-261 ORiginal Article Efficacy of Adalimumab in Korean Patients with Crohn s Disease Il Woong Sohn, Sung Tae Kim, Bun Kim, Hyun Jung Lee, Soo Jung Park,
More informationPerianal and Fistulizing Crohn s Disease: Tough Management Decisions. Jean-Paul Achkar, M.D. Kenneth Rainin Chair for IBD Research Cleveland Clinic
Perianal and Fistulizing Crohn s Disease: Tough Management Decisions Jean-Paul Achkar, M.D. Kenneth Rainin Chair for IBD Research Cleveland Clinic Talk Overview Background Assessment and Classification
More informationSurgical Outcomes of Crohn s Disease: A Single Institutional Experience in Taiwan. [J Soc Colon Rectal Surgeon (Taiwan) 2009;20:1-6]
J Soc Colon Rectal Surgeon (Taiwan) March 2009 Original Article Surgical Outcomes of Crohn s Disease: A Single Institutional Experience in Taiwan Ta-Wen Hsu 1,2 Feng-Fan Chiang 1 Hwei-Ming Wang 1 1 Division
More informationPosition of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy
Position of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy Stephen B. Hanauer, MD University of Chicago Potential Conflicts: Centocor/Schering, Abbott, UCB, Elan, Berlex, PDL Goals of Treatment
More informationIBD 101. Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition
IBD 101 Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition Objectives Identify factors involved in the development of inflammatory bowel
More informationLong-term outcome after infliximab for refractory ulcerative colitis
Journal of Crohn's and Colitis (2008) 2, 219 225 available at www.sciencedirect.com Long-term outcome after infliximab for refractory ulcerative colitis Marc Ferrante a, Séverine Vermeire a, Herma Fidder
More informationScheduled Maintenance Therapy with Infliximab Improves the Prognosis of Crohn s Disease: A Single Center Prospective Cohort Study in Japan
Tohoku J. Exp. Med., 2010, 220, 207-215 Infliximab Improves the Prognosis of Crohn s Disease 207 Scheduled Maintenance Therapy with Infliximab Improves the Prognosis of Crohn s Disease: A Single Center
More informationMohamed EL-hemaly Gastro- intestinal surgical center, Mansoura University.
Mohamed EL-hemaly Gastro- intestinal surgical center, Mansoura University. Chronic transmural inflammatory process of the bowel & affects any part of the gastro -intestinal tract from the mouth to the
More informationPatho Basic Chronic Inflammatory Bowel Diseases. Jürg Vosbeck Pathology
Patho Basic Chronic Inflammatory Bowel Diseases Jürg Vosbeck Pathology General Group of chronic relapsing diseases with chronic bloody or watery diarrhea Usually ulcerative colitis (UC) or Crohn s disease
More informationPathology and Diagnosis of Inflammatory Bowel Disease (IBD)
Inflammatory Bowel Disease Pathology and Diagnosis of Inflammatory Bowel Disease (IBD) JMAJ 45(2): 45 54, 2002 Takashi SHIMOYAMA Director, Department of Gastroenterology, Hyogo College of Medicine Abstract:
More informationFistulizing Crohn s Disease: The Aggressive Approach
Fistulizing Crohn s Disease: The Aggressive Approach Bruce E. Sands, MD, MS MGH Crohn s and Colitis Center and Gastrointestinal Unit Massachusetts General Hospital Boston, USA Case Presentation: Summary
More informationCrohn s disease is a heterogeneous inflammatory disorder
ORIGINAL ARTICLE Application of the Montreal classification for Crohn s disease to a single clinician database of 1015 patients Hugh J Freeman MD HJ Freeman. Application of the Montreal classification
More informationWorld Journal of Colorectal Surgery
World Journal of Colorectal Surgery Volume 6, Issue 5 2016 Article 4 Isolated Jejunal Crohn s Disease, A Diagnostic Dilemma Elise Biesboer BS Lacey Stelle MD Michelle M. Olson MD, MACM Paul Tender MD University
More informationIN THE DEVELOPMENT and progression of colorectal
Digestive Endoscopy 2014; 26 (Suppl. 2): 73 77 doi: 10.1111/den.12276 Treatment strategy of diminutive colorectal polyp
More informationTacrolimus therapy as an alternativ Titlemaintaining remission in patients w colitis. Author(s) Yamamoto, Shuji; Nakase, Hiroshi; M Masuda, Satohiro; Inui, Ken-ichi; C Citation Journal of clinical gastroenterolog
More informationThe Spectrum of IBD. Inflammatory Bowel Disease. Symptoms. Epidemiology. Tests for IBD. CD or UC? Inflamatory Bowel Disease. Fernando Vega, M.D.
The Spectrum of IBD Inflammatory Bowel Disease Fernando Vega, M.D. Epidemiology CD and UC together 1:400 UC Prevalence 1:500 UC Incidence 6-12K/annum CD Prevalence 1:1000 CD Incidence 3-6K/annum Symptoms
More informationIBD advanced course 2nd meeting IGA Meeting Hilton TLV
IBD advanced course 2nd meeting IGA Meeting Hilton TLV 6.1.2017 https://www.ibdvia.com Age Sanjeet is 24 years of age at diagnosis 1:Non- Predictors 2:Favorable prognosis 3:Poor prognosis Age- as a Prognostic
More informationAdvances in Inflammatory Bowel Diseases. Regional Institute of Gastroenterology and Hepatology Octavian Fodor Cluj-Napoca, Romania
Chapter 01 Inflammatory Bowel Diseases: Epidemiology and Natural History Roxana Zaharie 1,2 and Florin Zaharie 1,2 * 1 University of Medicine and Pharmacy Iuliu Hatieganu Cluj-Napoca, Romania 2 Regional
More informationThe small bowel capsule and management of patients
The small bowel capsule and management of patients with inflammatory bowel disease Arnaud Bourreille Institut des maladies de l appareil digestif (Imad), CHU Hôtel Dieu, Nantes, France The management of
More informationImpact of endoscopic monitoring in postoperative Crohn s disease patients already receiving pharmacological prevention of recurrence
1130-0108/2015/107/10/586-590 Revista Española de Enfermedades Digestivas Copyright 2015 Arán Ediciones, S. L. Rev Esp Enferm Dig (Madrid Vol. 107, N.º 10, pp. 586-590, 2015 ORIGINAL PAPERS Impact of endoscopic
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency London, 22 February 2007 Doc. Ref. CPMP/EWP/2284/99 Rev. 1 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT GUIDELINE ON THE DEVELOPMENT OF NEW MEDICINAL PRODUCTS FOR
More informationTreating Crohn s and Colitis in the ASC
Treating Crohn s and Colitis in the ASC Kimberly M Persley, MD Texas Digestive Disease consultants TASC Meeting Outline IBD 101 Diagnosis Treatment Burden of Disease Role of ASC Inflammatory Bowel Disease
More informationHow do I choose amongst medicines for inflammatory bowel disease. Maria T. Abreu, MD
How do I choose amongst medicines for inflammatory bowel disease Maria T. Abreu, MD Overview of IBD Pathogenesis Bacterial Products Moderately Acutely Inflamed Chronic Inflammation = IBD Normal Gut Mildly
More informationPrevious reports have suggested that youngonset
R E S E A R C H B R I E F Age-related Differences in the Clinical Course of Crohn s Disease in an Asian Population: A Retrospective Cohort Review SIU-TONG LAW AND KIN KONG LI From Department of Medicine
More informationEfficacy and Safety of Treatment for Pediatric IBD
Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Associate Professor of Clinical Pediatrics Division of Gastroenterology,
More informationGRANULOMATOUS COLITIS: SIGNIFICANCE OF INVOLVEMENT OF THE TERMINAL ILEUM
GASTROENTEROLOGY 64: 1071-1076, 1973 Copyright 1973 by The Williams & Wilkins Co. Vol. 64, No.6 Printed in U.S.A. GRANULOMATOUS COLITIS: SIGNIFICANCE OF INVOLVEMENT OF THE TERMINAL ILEUM JAMES A. NELSON,
More informationCertain genes passed on from parent to child increase the risk of developing Crohn's disease, if the right trigger occurs.
Topic Page: Crohn's disease Definition: Crohn's disease from Benders' Dictionary of Nutrition and Food Technology Chronic inflammatory disease of the bowel, commonly the terminal ileum, of unknown aetiology,
More informationMucosal healing: does it really matter?
Oxford Inflammatory Bowel Disease MasterClass Mucosal healing: does it really matter? Professor Jean-Frédéric Colombel, New York, USA Oxford Inflammatory Bowel Disease MasterClass Mucosal healing: does
More informationWhich is the Safest Strategy to Treat Moderate to Severe IBD?
Which is the Safest Strategy to Treat Moderate to Severe IBD? David G. Binion, M.D. Co-Director, Inflammatory Bowel Disease Center Director, Translational Inflammatory Bowel Disease Research Visiting Professor
More informationEffect of Adalimumab on an Enterocutaneous Fistula in Patients with Crohn s Disease: A Case Series
CASE REPORT Effect of Adalimumab on an Enterocutaneous Fistula in Patients with Crohn s Disease: A Case Series Kaori Fujiwara, Takuya Inoue, Naoki Yorifuji, Munetaka Iguchi, Taisuke Sakanaka, Ken Narabayashi,
More informationInflammatory Bowel Disease Cohort Studies in Korea: Present and Future
SPECIAL REVIEW: IBD and Epidemiology in Asia ISSN 1598-9100(Print) ISSN 2288-1956(Online) http://dx.doi.org/10.5217/ir.2015.13.3.213 Intest Res 2015;13(3):213-218 Inflammatory Bowel Disease Cohort Studies
More informationPersonalized Medicine in IBD
Personalized Medicine in IBD Anita Afzali MD, MPH Assistant Professor of Medicine Director, Inflammatory Bowel Diseases Program University of Washington Harborview Medical Center CCFA April 2 nd, 2016
More informationCrohn's Disease. The What, When, and Why of Treatment
Crohn's Disease The What, When, and Why of Treatment Sunanda Kane, MD, FACG Professor of Medicine Department of Gastroenterology and Hepatology Mayo Clinic Rochester, MN In my lecture today, I will be
More informationTakayuki; Eguchi, Susumu; Kanematsu. Citation Pediatric surgery international, 27
NAOSITE: Nagasaki University's Ac Title Author(s) Endoscopic balloon dilatation for c jejunum in an infant. Mochizuki, Kyoko; Obatake, Masayuki Takayuki; Eguchi, Susumu; Kanematsu Citation Pediatric surgery
More informationTreatment of Inflammatory Bowel Disease. Michael Weiss MD, FACG
Treatment of Inflammatory Bowel Disease Michael Weiss MD, FACG What is IBD? IBD is an immune-mediated chronic intestinal disorder, characterized by chronic or relapsing inflammation within the GI tract.
More informationGASTROENTEROLOGY. Official Publication of the American Gastroenterological Association. CoPYRIGHT 1975 THE WILLIAMS & WILKINS Co.
GASTROENTEROLOGY Official Publication of the American Gastroenterological Association CoPYRIGHT 1975 THE WILLIAMS & WILKINS Co. Vol68 April 1975 Number 4 ALIMENTARY TRACT CLINICAL PATTERNS IN CROHN'S DISEASE:
More informationCrohn's disease of the duodenum
Crohn's disease of the duodenum F. WARREN NUGENT,' M. RICHMOND,2 AND S. K. PARK3 Gut, 1977, 18, 115-120 From the Department of Gastroenterology, Lahey Clinic Foundation, Boston, Massachusetts, USA SUMMARY
More informationDr David Epstein Vincent Pallotti Hospital and University of Cape Town
Inflammatory Bowel Disease Management in South Africa in 2016 Pharmaceutical Care Management Association Dr David Epstein Vincent Pallotti Hospital and University of Cape Town Inflammatory Bowel Disease
More informationAnne Griffiths MD, FRCPC. SickKids Hospital, University of Toronto. Buenos Aires, August 16, 2014
Management and Medical Therapies for Crohn disease: strategies to enhance mucosal healing Anne Griffiths MD, FRCPC SickKids Hospital, University of Toronto Buenos Aires, August 16, 2014 New onset Crohn
More informationet al.. Long-term outcome of perianal fistulizing Crohn s disease treated with infliximab..
Long-term outcome of perianal fistulizing Crohn s disease treated with infliximab. Guillaume Bouguen, Laurent Siproudhis, Emmanuel Gizard, Timothée Wallenhorst, Vincent Billioud, Jean-François Bretagne,
More informationEndoscopy in IBD. F.Hartmann K.Kasper-Kliniken (St.Marienkrankenhaus) Frankfurt/M.
F.Hartmann K.Kasper-Kliniken (St.Marienkrankenhaus) Frankfurt/M. F.Hartmann@em.uni-frankfurt.de Indications for endoscopy Diagnosis Management Surveillance Diagnosis Single most valuable tool: ileocolonoscopy
More informationIBD 101. Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition
IBD 101 Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition Objectives Identify factors involved in the development of inflammatory bowel
More informationEuropean evidence-based consensus on the use of imaging techniques in inflammatory bowel disease diagnosis and management
European evidence-based consensus on the use of imaging techniques in inflammatory bowel disease diagnosis and management J. Martin-Comin Hospital U. Bellvitge Hospitalet de Llobregat Spain THE EUROPEAN
More informationThe Effect of Medical Treatment on Patients with Fistulizing Crohn s Disease: A Retrospective Study
ORIGINAL ARTICLE The Effect of Medical Treatment on Patients with Fistulizing Crohn s Disease: A Retrospective Study Norimitsu Uza, Hiroshi Nakase, Satoru Ueno, Satoko Inoue, Sakae Mikami, Hiroyuki Tamaki,
More informationDiarrhea may be: Acute (short-term, usually lasting several days), which is usually related to bacterial or viral infections.
Pediatric Gastroenterology Conditions Evaluated and Treated Having a child suffer with abdominal pain, chronic eating problems, or other gastrointestinal disorders can be a very trying time for a parent.
More informationAzathioprine for Induction and Maintenance of Remission in Crohn s Disease
Azathioprine for Induction and Maintenance of Remission in Crohn s Disease William J. Sandborn, MD Chief, Division of Gastroenterology Director, UCSD IBD Center Objectives Azathioprine as induction and
More informationIleo-rectal anastomosis for Crohn's disease of
Ileo-rectal anastomosis for Crohn's disease of the colon W. N. W. BAKER From the Research Department, St Mark's Hospital, London Gut, 1971, 12, 427-431 SUMMARY Twenty-six cases of Crohn's disease of the
More informationTrends in Biologic Therapy for Crohn s Disease: Where Are We and Where Are We Going? CME
Trends in Biologic Therapy for Crohn s Disease: Where Are We and Where Are We Going? CME Uma Mahadevan-Velayos, MD Supported by independent educational grants from View this activity online at: medscape.org/column/crohns
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/38545 holds various files of this Leiden University dissertation. Author: Molendijk, Ilse Title: Mesenchymal stromal cell therapy for Crohn's disease :
More informationThe Natural History of Fistulizing Crohn s Disease in Olmsted County, Minnesota
GASTROENTEROLOGY 2002;122:875 880 CLINICAL RESEARCH The Natural History of Fistulizing Crohn s Disease in Olmsted County, Minnesota DAVID A. SCHWARTZ,* EDWARD V. LOFTUS, JR.,* WILLIAM J. TREMAINE,* REMO
More informationCCFA. Crohns Disease vs UC: What is the best treatment for me? November
CCFA Crohns Disease vs UC: What is the best treatment for me? November 8 2009 Ellen J. Scherl,, MD, FACP,AGAF Roberts Inflammatory Bowel Disease Center Weill Medical College Cornell University New York
More informationThe Incidence Rate of Inflammatory Bowel Disease in an Urban Area of Iran: A Developing Country
32 Original Article The Incidence Rate of Inflammatory Bowel Disease in an Urban Area of Iran: A Developing Country Mohammad Javad Zahedi 1, Sodaif Darvish Moghadam 1, Mehdi Hayat Bakhsh Abbasi 1, Masood
More informationTHE OUTCOME OF INFLAMMATORY BOWEL DISEASE
THE OUTCOME OF INFLAMMATORY BOWEL DISEASE R G Farmer SING MED J. 1989; No 3: 89-93 Crohn's disease and ulcerative colitis have become among the most frequently encountered chronic digestive diseases. Two
More informationINTRODUCTION. Key Words: Crohn disease; C-reactive protein; Clinical course. ORiginal Article
Gut and Liver, Vol. 1, No. 4, July 216, pp. 595-63 ORiginal Article Disease Phenotype, Activity and Clinical Course Prediction Based on C-Reactive Protein Levels at Diagnosis in Patients with Crohn s Disease:
More informationFocally Enhanced Gastritis in Newly Diagnosed Pediatric Inflammatory Bowel Disease
Focally Enhanced Gastritis in Newly Diagnosed Pediatric Inflammatory Bowel Disease The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters
More informationMedical Management of Intestinal Strictures
Medical Management of Intestinal Strictures Subrata Ghosh, FRCP, FRCPE, FRCPC, AGAF, FCAHS Professor of Translational Medicine Director of the Institute of Translational Medicine University of Birmingham,
More informationCase Discussion. Nutrition in IBD. Rémy Meier MD. Ulcerative colitis. Crohn s disease
26.08.2017 Case Discussion Nutrition in IBD Crohn s disease Ulcerative colitis Rémy Meier MD Case Presentation 30 years old female, with diarrhea for 3 months Shool frequency 3-4 loose stools/day with
More informationCitation Acta medica Nagasakiensia. 1988, 33
NAOSITE: Nagasaki University's Ac Title Author(s) Surgery for complications by divert Harada, Yoshihide; Sato, Tetsuya; O Oh, Shimei; Obatake, Masayuki; Kawa Takatoshi; Tomita, Masao Citation Acta medica
More informationDevelopment of Optimum Information System for Health Management in Patients with Crohn s Disease
, pp.224-229 http://dx.doi.org/10.14257/astl.2014.53.47 Development of Optimum Information System for Health Management in Patients with Crohn s Disease Seong-Ran Lee ¹Department of Medical Information,
More informationTowards Precision Medicine in Inflammatory Bowel Diseases
Precision Medicine and Biomarkers Leaders Summit. Munich September 13-14, 2018 Towards Precision Medicine in Inflammatory Bowel Diseases ANDRÉS HURTADO-LORENZO, Ph.D. SENIOR DIRECTOR OF TRANSLATIONAL RESEARCH
More informationIBD Tools to Aid in the Accurate Diagnosis of Inflammatory Bowel Disease
IBD Tools to Aid in the Accurate Diagnosis of Inflammatory Bowel Disease Inflammatory Bowel Disease Experts in Autoimmunity Inova Diagnostics offers a complete array of methods to aid in the diagnosis
More informationSurgical Management of IBD. Val Jefford Grand Rounds October 14, 2003
Surgical Management of IBD Val Jefford Grand Rounds October 14, 2003 Introduction Important Features Clinical Presentation Evaluation Medical Treatment Surgical Treatment Cases Overview Introduction Two
More informationWhat is Crohn's disease?
What is Crohn's disease? Crohn's disease is a chronic inflammatory disorder that causes inflammation of the digestive tract. It can affect any area of the GI tract, from the mouth to the anus, but it most
More informationIBD. Crohn s. Outline. Ulcerative colitis versus Crohn s disease: is biopsy useful? UC vs. Crohn s? Is it easy? Biopsy settings 21/07/2017 IBD
Outline Ulcerative colitis versus Crohn s disease: is biopsy useful? Roger Feakins Colorectal biopsies Ileal and upper GI biopsies Special situations New techniques Summary Inflammatory bowel disease (IBD)
More informationCrohn's disease: natural history and treatment J. E. LENNARD-JONES. College and St Mark's Hospitals, London
Postgrad. med. J. (September 1968) 44, 674-678. University Crohn's disease: natural history and treatment J. E. LENNARD-JONES AN EXrENSIVE literature is now available on the pathological anatomy and its
More informationPresence of pseudopolyps in ulcerative colitis is associated with a higher risk for treatment escalation
ORIGINAL ARTICLE Annals of Gastroenterology (2019) 32, 1-6 Presence of pseudopolyps in ulcerative colitis is associated with a higher risk for treatment escalation Dimitrios S. Politis a, Konstantinos
More informationFatal Gastrointestinal Perforations in sudden death cases in Last 10 years at UMMC- Malaysia
Fatal Gastrointestinal Perforations in sudden death cases in Last 10 years at UMMC- Malaysia Dr. OP Murty, Dr. Lye Yik Fan, Dr. Tan Ley Siang, Dr. Nurull Eddayu binti Hasbullah, Dr. Nurul Azwa binti Mohd
More informationCrohn's Disease. The What, When, and Why of Treatment
Crohn's Disease The What, When, and Why of Treatment Brian Feagan, MD, FACG Professor of Medicine and Epidemiology and Biostatistics Director, Robarts Clinical Trials Robarts Research Institute University
More informationModern Management of Perianal Fistulas in Crohn s Disease (PFCD): Future Directions
Modern Management of Perianal Fistulas in Crohn s Disease (PFCD): Future Directions Rami Ismail, Pharm.D., BCPS, BCCCP, CACP Lead Clinical staff Pharmacist, Cleveland Clinic Abu Dhabi Disclosure Information
More informationMedical therapies and IBD
Medical therapies and IBD Although there is no cure for IBD, there are many treatment options available. There is no standard treatment for IBD that is effective in all situations or for all patients,
More informationCrohn's Disease. What causes Crohn s disease? What are the symptoms?
Crohn's Disease Crohn s disease is an ongoing disorder that causes inflammation of the digestive tract, also referred to as the gastrointestinal (GI) tract. Crohn s disease can affect any area of the GI
More information